The Toro Company Increases Regular Quarterly Cash Dividend

BLOOMINGTON, Minn.--(BUSINESS WIRE)-- The Toro Company (NYSE: TTC) today announced that its board of directors has declared a $0.30 per share regular quarterly cash dividend, an increase of 14 percent over the previous $0.2625 per share. This dividend is payable on January 11, 2022, to shareholders of record on December 28, 2021.

About The Toro Company

The Toro Company (NYSE: TTC) is a leading worldwide provider of innovative solutions for the outdoor environment including turf and landscape maintenance, snow and ice management, underground utility construction, rental and specialty construction, and irrigation and outdoor lighting solutions. With sales of $3.4 billion in fiscal 2020, The Toro Company’s global presence extends to more than 125 countries through a family of brands that includes Toro, Ditch Witch, Exmark, BOSS Snowplow, Ventrac, American Augers, Subsite Electronics, HammerHead, Trencor, Unique Lighting Systems, Irritrol, Hayter, Pope, Perrot, Lawn-Boy and Radius HDD. Through constant innovation and caring relationships built on trust and integrity, The Toro Company and its family of brands have built a legacy of excellence by helping customers work on golf courses, sports fields, construction sites, public green spaces, commercial and residential properties and agricultural operations. For more information, visit www.thetorocompany.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211214006292/en/

Investor Relations
Julie Kerekes
Treasurer and Sr. Managing Director, Global Tax
and Investor Relations
(952) 887-8846, [email protected]

Media Relations
Branden Happel
Senior Manager, Public Relations
(952) 887-8930, [email protected]

Source: The Toro Company

You May Also Be Interested In

• The Toro Company Elects David Huml to Board of Directors
• Hitachi Rail launches ‘Enhanced by HMAX™’, committing to embed technology in all new rolling stock from 2027
• Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity